Enanta Pharmaceuticals宣布,其研发的口服每日一次KIT抑制剂EDP-978已在一期临床试验中完成首例受试者给药。该药物目前正针对荨麻疹治疗进行开发,标志着公司在该疾病领域取得重要研究进展。
Enanta Pharmaceuticals宣布,其研发的口服每日一次KIT抑制剂EDP-978已在一期临床试验中完成首例受试者给药。该药物目前正针对荨麻疹治疗进行开发,标志着公司在该疾病领域取得重要研究进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.